JPWO2022045273A1 - - Google Patents
Info
- Publication number
- JPWO2022045273A1 JPWO2022045273A1 JP2022545716A JP2022545716A JPWO2022045273A1 JP WO2022045273 A1 JPWO2022045273 A1 JP WO2022045273A1 JP 2022545716 A JP2022545716 A JP 2022545716A JP 2022545716 A JP2022545716 A JP 2022545716A JP WO2022045273 A1 JPWO2022045273 A1 JP WO2022045273A1
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2405—Glucanases
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/0105—Alpha-N-acetylglucosaminidase (3.2.1.50)
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020145100 | 2020-08-28 | ||
| PCT/JP2021/031431 WO2022045273A1 (ja) | 2020-08-28 | 2021-08-27 | α－Ｎ－アセチルグルコサミニダーゼの変異体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPWO2022045273A1 true JPWO2022045273A1 (ja) | 2022-03-03 |
Family
ID=80353369
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022545716A Pending JPWO2022045273A1 (ja) | 2020-08-28 | 2021-08-27 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230323326A1 (ja) |
| EP (1) | EP4198129A1 (ja) |
| JP (1) | JPWO2022045273A1 (ja) |
| KR (1) | KR20230056714A (ja) |
| CN (1) | CN116234901A (ja) |
| AU (1) | AU2021333365A1 (ja) |
| BR (1) | BR112023003342A2 (ja) |
| CA (1) | CA3192771A1 (ja) |
| IL (1) | IL300887A (ja) |
| MX (1) | MX2023002346A (ja) |
| TW (1) | TW202227630A (ja) |
| WO (1) | WO2022045273A1 (ja) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117625581B (zh) * | 2024-01-24 | 2024-03-26 | 云南师范大学 | 一种N-乙酰氨基葡萄糖苷酶突变体Ea2F及其应用 |
| CN117737037B (zh) * | 2024-02-07 | 2024-04-19 | 中国林业科学研究院高原林业研究所 | 一种N-乙酰氨基葡萄糖苷酶突变体De266LΔ6及其制备与应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPN674895A0 (en) | 1995-11-23 | 1995-12-14 | Women's And Children's Hospital | Synthetic mammalian alpha-N-acetylglucosaminidase and genetic sequences encoding same |
| JP6063380B2 (ja) * | 2010-06-25 | 2017-01-18 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | サンフィリポ症候群ｂ型の処置 |
| WO2012063799A1 (ja) | 2010-11-08 | 2012-05-18 | 日本ケミカルリサーチ株式会社 | 新規発現ベクター |
| US9657310B2 (en) | 2012-04-27 | 2017-05-23 | Jcr Pharmaceuticals Co., Ltd. | Expression vector |
| RU2718248C2 (ru) * | 2014-05-14 | 2020-03-31 | Эстев Фармасьютикалс, С.А. | Аденоассоциированные вирусные векторы для лечения лизосомных болезней накопления |
| EA201991577A1 (ru) | 2016-12-26 | 2019-12-30 | Джей Си Ар ФАРМАСЬЮТИКАЛЗ КО., ЛТД. | Новые антитела против рецептора трансферрина человека, способные преодолевать гематоэнцефалический барьер |
-
2021
- 2021-08-27 CN CN202180051073.1A patent/CN116234901A/zh active Pending
- 2021-08-27 TW TW110131793A patent/TW202227630A/zh unknown
- 2021-08-27 IL IL300887A patent/IL300887A/en unknown
- 2021-08-27 CA CA3192771A patent/CA3192771A1/en active Pending
- 2021-08-27 US US18/022,992 patent/US20230323326A1/en active Pending
- 2021-08-27 EP EP21861695.1A patent/EP4198129A1/en active Pending
- 2021-08-27 BR BR112023003342A patent/BR112023003342A2/pt unknown
- 2021-08-27 JP JP2022545716A patent/JPWO2022045273A1/ja active Pending
- 2021-08-27 WO PCT/JP2021/031431 patent/WO2022045273A1/ja unknown
- 2021-08-27 KR KR1020237009458A patent/KR20230056714A/ko unknown
- 2021-08-27 AU AU2021333365A patent/AU2021333365A1/en active Pending
- 2021-08-27 MX MX2023002346A patent/MX2023002346A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4198129A1 (en) | 2023-06-21 |
| AU2021333365A1 (en) | 2023-03-16 |
| MX2023002346A (es) | 2023-03-22 |
| KR20230056714A (ko) | 2023-04-27 |
| US20230323326A1 (en) | 2023-10-12 |
| BR112023003342A2 (pt) | 2023-04-04 |
| CN116234901A (zh) | 2023-06-06 |
| TW202227630A (zh) | 2022-07-16 |
| IL300887A (en) | 2023-04-01 |
| CA3192771A1 (en) | 2022-03-03 |
| WO2022045273A1 (ja) | 2022-03-03 |